AGL Angle Plc

TIDMAGL

RNS Number : 9296R

Angle PLC

11 November 2011

 
 For immediate release   11 November 2011 
 

ANGLE plc ("the Company")

Parsortix Update

VALIDATION FOR PROSTATE CANCER

ANGLE plc (AIM : AGL) is delighted to announce that Parsortix Inc ("Parsortix"), its 90% owned portfolio company which specialises in medical diagnostics has achieved another important milestone by confirming that its cell separation device can capture prostate cancer cells.

ANGLE has previously established that its Parsortix separation technology can capture breast cancer cells added to blood. New experiments have now shown that the Parsortix separation technology works equally well with cultured prostate cancer cells added to blood.

This new validation is an important step towards demonstrating that, unlike existing antibody affinity based technology, the Parsortix separation technology works well with any solid tumour cancers without the need for modification.

The Parsortix separation technology offers the potential for a CTC (circulating tumour cell) isolation, capture and characterisation device, for:

   --     early detection of cancer; 
   --     monitoring of cancer patients during treatment; and 
   --     post-treatment monitoring of cancer patients in remission. 

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"The successful capture and identification of prostate cancer cells added to blood further substantiates the potential for the Parsortix separation technology to become a market-leading product, which is simple, effective and affordable."

For further information:

 
 ANGLE plc                                    01483 685830 
 Andrew Newland, Chief Executive 
  Ian Griffiths, Finance Director 
 Cenkos Securities 
  Stephen Keys, Adrian Hargrave (Nominated 
  adviser) 
  Andy Roberts (Sales)                        020 7397 8900 
 Buchanan 
  Lisa Baderoon                               020 7466 5000 
 Scott Harris 
  Stephen Scott, James O'Shaughnessy, 
  Harry Dee                                   0207 653 0030 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAKFFFLKFFEF

Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024

Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024